within Pharmacolibrary.Drugs.ATC.J;

model J01XD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 5.5e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XD03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ornidazole is a nitroimidazole class antimicrobial agent used primarily for the treatment of infections caused by anaerobic bacteria and protozoa. It is effective against conditions such as amoebiasis, giardiasis, and trichomoniasis, and is approved for clinical use in many countries, though not in all global markets.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from studies on healthy adult volunteers following a single oral dose of ornidazole.</p><h4>References</h4><ol><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=\"https://doi.org/10.2165/00003088-199936050-00004\">10.2165/00003088-199936050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10384859/\">https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Zhang, C, et al., &amp; Liu, D (2019). Mucoadhesive buccal film containing ornidazole and dexamethasone for oral ulcers: in vitro and in vivo studies. <i>Pharmaceutical development and technology</i> 24(1) 118–126. DOI:<a href=\"https://doi.org/10.1080/10837450.2018.1428814\">10.1080/10837450.2018.1428814</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29334299/\">https://pubmed.ncbi.nlm.nih.gov/29334299</a></p></li><li><p>Kumar, YS, et al., &amp; Paradkar, AR (2007). Effect of rifampicin pretreatment on the transport across rat intestine and oral pharmacokinetics of ornidazole in healthy human volunteers. <i>Drug metabolism and drug interactions</i> 22(2-3) 151–163. DOI:<a href=\"https://doi.org/10.1515/dmdi.2007.22.2-3.151\">10.1515/dmdi.2007.22.2-3.151</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17708065/\">https://pubmed.ncbi.nlm.nih.gov/17708065</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XD03;
